Certified by Founder Lodge
Illimis Therapeutics
Korea, Republic Of - Seoul
START UP
1 Disclosed Funding Rounds $42,000,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiate
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 15 ,2025 | Series B | $42,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Clairity, Inc. | $43,000,000 | (Nov 14, 2025)
Songscription | $5,000,000 | (Nov 14, 2025)
Park Loyalty | Undisclosed Amount | (Nov 14, 2025)
Carbon(US) | $60,000,000 | (Nov 14, 2025)
CoRun.ai | $3,500,000 | (Nov 14, 2025)
